Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 5107 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed477    
    Printed24    
    Emailed0    
    PDF Downloaded108    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 1999  |  Volume : 41  |  Issue : 2  |  Page : 100-103

Drug Treatment in Schizophrenia : Issues of Comparability and Costs


1 Resident, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore-560029, India
2 Associate Professor, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore-560029, India
3 Professor & Head, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore-560029, India

Correspondence Address:
Pratima Murthy
Associate Professor, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore-560029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21455370

Rights and PermissionsRights and Permissions

Pharmacological intervention is the commonest mode of managing patients with schizophrenia. Both clinicians and patients are concerned that antipsyohotic drugs are costly and contribute to poor drug compliance in India. This study compared the equivalent doses of antipsychotic drugs and their costs across brands. Results show that antipsychotic drugs are affordable and are comparable to drug treatment costs of other physical illnesses. However, coprescription of drugs add to the burden. Numerous brands and a 2-2Vz fold difference in cost raises many concerns including that of drug bioavailability. Hence, the authors recommend consensus and formulation of guidelines for the pharmacological management of schizophrenia.



[PDF]*

        

Print this article         Email this article